A Phase 4 interventional study of olanzapine and haloperidol in Bipolar Disorder, sponsored by Eli Lilly and Company. Terminated at 1 site in Sweden. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2008-10-07.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.
Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 28th largest by enrollment, is one of 5 that started in 2004, is one of 19 in phase 4, and was the 24th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 120 across the 28 interventional studies. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Bipolar Disorder by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 5 (26%) have results posted.
Among the 20 studies in Bipolar Disorder by Eli Lilly and Company, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2004, is one of 11 in phase 4, and was the 16th registered.
Eli Lilly and Company’s Bipolar Disorder studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing olanzapine in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 20 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the efficacy and total costs of olanzapine versus commonly used conventional antipsychotics in Sweden.
The primary objective is to show that the efficacy of olanzapine is non-inferior to the conventional antipsychotics haloperidol or zuclopentixol in the treatment of an acute manic or mixed episode of bipolar disorder. Efficacy is defined as time to remission, as measured by the total scores of the Young Mania Rating Scale (Y-MRS), MADRS-S, and Clinical Global Impression - Bipolar (CGI-BP). Time from baseline to remission is defined as the primary efficacy measure. Remission is defined as a Y-MRS score \<=12 AND a MADRS-S score \<=12 AND CGI-BP = 1 or 2.
Secondary efficacy assessments will include time from baseline to
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be given olanzapine
Drug: olanzapine
Patients will be given either haloperidol or zuclopentixol
Drug: haloperidol · Drug: zuclopentixol
physician determined dose, oral, daily, 5 months
Also known as: LY170053, Zyprexa
physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
Time to remission by Young Mania Rating Scale, MADRS-S and CGI-BP
Time frame: 5 months
Resource utilization Clinical Report Form (RUCRF)
Time frame: 5 months
Disability free day assessment (DFDA)
Time frame: 5 months
Medication compliance
Time frame: 5 months
Medical Outcomes Study 36-Item Short Form Health Survey (SF-36)
Time frame: 5 months
Euro Qol instrument
Time frame: 5 months
Drug Attitude Inventory (DAI)
Time frame: 5 months
Response by Y-MRS
Time frame: 5 months
Frequency of and time to relapse into mania by Y-MRS and CGI-BP
Time frame: 5 months
Frequency of and time to switch to depression by MADRS-S and DSRS
Time frame: 5 months
Time to remission in patients with psychotic features by SCID-I judgement, Y-MRS item 8 and PANSS positive items mean sum
Time frame: 5 months
Adverse events
Time frame: 5 months
The record gives a start of Oct 2004, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine